Orelabrutinib Phase 2b Lupus Study Meets Primary Endpoint
In a 187-patient Phase 2b study in systemic lupus erythematosus, orelabrutinib 75 mg once daily achieved a 57.1% SRI-4...
eClinical Tech News
Silexion Submits Pancreatic Cancer Trial App in Israel
Preclinical data for SIL204 reported up to 99.7% cancer cell inhibition across multiple KRAS mutations, and recently completed two-species...
Beacon’s XLRP Gene Therapy Trial Treats Its First Patient
Interim Phase 2 data for laru-zova have shown sustained gains on low-luminance visual acuity and microperimetry, with participants generally...
Arch Biopartners’ Phase II AKI Trial Gets Ethics Approval
Arch Biopartners’ Phase II study in cardiac surgery–associated acute kidney injury (CS-AKI) targets enrollment of 240 on-pump patients, randomizing...
Evolveimmune Initiates Phase 1 Dosing for Solid Tumors
No efficacy or safety data were disclosed. EvolveImmune has dosed the first subject in EIU-104101 (NCT07217171), a first-in-human Phase...
MRT-2359 Shows Compelling Activity in Prostate Cancer Trial
In an interim Phase 1/2 readout in metastatic castration‑resistant prostate cancer (mCRPC), the combination of Monte Rosa’s GSPT1 degrader...
Tenax Therapeutics Reveals Blinded Sample Size Assessment Data
Tenax’s blinded sample size re-estimation in its Phase 3 LEVEL study indicates the trial retains well over 90% power...
Breakthrough ADAPT Trial Enrollment Complete for Olastrocel
A completed safety review by an independent DSMB reported no significant adverse events, and enrollment has now closed in...
Tiziana’s Phase 2 Alzheimer’s Trial Doses First Patient
Tiziana Life SciencesLife Sciences has dosed the first patient in a randomized, placebo-controlled Phase 2 study of intranasal foralumab...
A Vulnerable Infant Gut: The Critical Need for Restoration
Across multiple infant cohorts, up to 24% of U.S. infants had no detectable Bifidobacterium, with the absence rising to...